Leucocyte‐ and platelet‐rich fibrin block for bone augmentation procedure: A proof‐of‐concept study

Cortellini, Simone; Castro, Ana Belén Salamanca; Temmerman, Andy; Dessel, Jeroen Van; Pinto, Nelson; Jacobs, Reinhilde; Quirynen, Marc

doi:10.1111/jcpe.12877

Cited by 62 publications

(67 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another interesting observation has been that with even lower speeds and a shorter time (700 rpm, 60 g force for 3 minutes), a liquid version of PRF could be obtained . This new formulation was given the working name injected platelet‐rich fibrin (I‐PRF) due to its hypothesized ability to be solely injected into defects or combined with various biomaterials similar to PRP but without any anticoagulants . On the other hand, investigators introduced another modification – concentrated growth factor (CGF) .…”

Section: Introductionmentioning

confidence: 99%

Quantification of growth factors in advanced platelet‐rich fibrin and concentrated growth factors and their clinical efficacy as adjunctive to the GTR procedure in periodontal intrabony defects

Lei

Han

et al. 2019

Journal of Periodontology

View full text Add to dashboard Cite

Background:The development of platelet concentrated biomaterials has gained increasing awareness for regenerative medicine. With different protocol, derivatives such as advanced platelet-rich fibrin (A-PRF), injected platelet-rich fibrin, and concentrated growth factor (CGF) have been demonstrated effectively in preclinical and clinical studies. The aim of this study was to compare the level of growth factors releasing from A-PRF and CGF, and their clinical efficacy in the regenerative management of intrabony defects (IBDs).Methods: Thirty-two blood samples were collected from eight healthy donors and assessed for platelet-derived growth factor-, vascular endothelial growth factor, bone morphogenetic protein-2, and transforming growth factor-1 release at indicated times. In addition, the clinical records of 45 patients (15 per group) who had undergone guided tissue regeneration (GTR) with or without A-PRF/CGF were retrieved. The probing depth (PD) and clinical attachment level (CAL) were recorded preoperatively and 6 months postoperatively. Intrabony component (IC) depth, radiographic bone level (RBL), and bone defect filling were assessed radiographically. Results:A-PRF had a looser fibrin network than the CGF but presented larger amounts of growth factors with a more sustained release period. Although there was no difference in PD reduction, CAL gain, RBL height change and defect filling (%) between A-PRF and CGF group, both achieved a more favorable clinical result in IC height reduction and defect filling (%) than the control. Conclusions:A-PRF and CGF have the ability to stimulate a continual and steady release of total growth factors over a 14-day period. A-PRF and CGF show a similar effectiveness in periodontal bone regeneration with a potential benefit of improving GTR outcomes in IBD treatment. K E Y W O R D Sbone substitutes, growth factors, guided tissue regeneration, periodontitis, platelet-rich fibrin 462

show abstract

Section: Introductionmentioning

confidence: 99%

Quantification of growth factors in advanced platelet‐rich fibrin and concentrated growth factors and their clinical efficacy as adjunctive to the GTR procedure in periodontal intrabony defects

Lei

Han

et al. 2019

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…In 10 patients, successful horizontal ridge augmentation that enabled subsequent implant placement was observed at 5–8 months after treatment with an L‐PRF block prepared by mixing a particulated DBBM graft with chopped L‐PRF membranes (Cortellini, Castro, Temmerman, Vandessel & Pinto, ). After 5–8 months, CBCT scans showed a horizontal bone gain ranging between 4.4 mm and 5.3 mm, while the mean volumetric graft resorption was 15.6% (±6.7).…”

Section: Resultsmentioning

confidence: 99%

“…Although few studies suggested that combined therapies where APCs were associated with grafts and/or cells were able to promote ridge augmentation (Cortellini et al., ; Eskan et al., ; Filho Cerruti et al., ; Marx et al., ; Moussa et al., ) and sinus augmentation (Anitua et al., ; Choukroun et al., ; Inchingolo et al., ; Kassolis & Reynolds, ; Poeschl et al., ; Riaz et al., ), RCTs are needed to clarify whether APCs are associated to a real clinical benefit and which APC performs better (Appendix S5 and S6).…”

Section: Discussionmentioning

confidence: 99%

The use of bioactive factors to enhance bone regeneration: A narrative review

Donos

Dereka

Calciolari

2019

J Clinic Periodontology

View full text Add to dashboard Cite

Aim This review critically appraises the available knowledge on the pre‐clinical and clinical use of bioactive factors for bone regeneration in the cranial and maxillofacial area. Materials and Methods The use of growth factors, amelogenins and autologous platelet concentrates (APCs) for bone regeneration was reviewed in a systematic manner. More specifically, pre‐clinical and clinical studies on ridge preservation, alveolar ridge augmentation, regeneration of peri‐implant defects and sinus augmentation models were considered. Results Amongst different bioactive factors, the highest pre‐clinical and clinical evidence of a positive effect on bone formation is associated with rhBMP‐2 and the lowest with amelogenins. While APCs seem to accelerate clinical healing and reduce postoperative discomfort, there is insufficient and contrasting evidence of a significant effect on hard tissue regeneration for the different clinical applications. Conclusions Although there is increasing evidence that bioactive factors might enhance the bone regeneration process, the great heterogeneity of the available studies and the limited number of RCTs do not allow to draw robust conclusions. Issues that still need to be investigated include the optimal carriers for bioactive agents (direct vs. indirect), the dosage, the timing of administration, as well as the possibility of combining different agents to promote synergistic effects.

show abstract

“…While comparative studies are needed, many authors have deviated from reporting g‐forces based on international centrifugation standards that effectively report g‐force at the bottom of centrifugation tubes. We have previously demonstrated how the report of RCF values at the RCFclot is not only a deviation from the standard method, but one that is subject to additional error and inaccuracies as seen most recently in the work of Cortellini et al (Fig. , Supplemental Fig.…”

mentioning

confidence: 89%

Reply from authors: RE: Optimized platelet‐rich fibrin with the low‐speed concept: Growth factor release, biocompatibility, and cellular response

Miron

Choukroun

Ghanaati

2018

Journal of Periodontology

View full text Add to dashboard Cite

Leucocyte‐ and platelet‐rich fibrin block for bone augmentation procedure: A proof‐of‐concept study

Abstract: L-PRF Block may be a suitable technique to augment deficient alveolar ridges.

Cited by 62 publications

References 31 publications

Quantification of growth factors in advanced platelet‐rich fibrin and concentrated growth factors and their clinical efficacy as adjunctive to the GTR procedure in periodontal intrabony defects

Quantification of growth factors in advanced platelet‐rich fibrin and concentrated growth factors and their clinical efficacy as adjunctive to the GTR procedure in periodontal intrabony defects

The use of bioactive factors to enhance bone regeneration: A narrative review

Reply from authors: RE: Optimized platelet‐rich fibrin with the low‐speed concept: Growth factor release, biocompatibility, and cellular response

Contact Info

Product

Resources

About